First, recent laboratory evidence suggests that the epigenetic silencing of CD38 in PCa cells enhances NAD availability, thereby conferring a survival advantage to tumor-initiating cells by improving mitochondrial function (43, 44). The gene discussed is CD38; the disease is posterior cortical atrophy.